Results 201 to 210 of about 10,510,072 (298)

Factors demonstrating readiness for clinical pharmacy services

American Journal of Health-System Pharmacy, 2019
Courtenay Gilmore, Wilson, Irene Park, Ulrich, Mollie Ashe, Scott   +2 more
openaire   +2 more sources

What Happens to the General Practitioner When the Pharmacist Tests for Strep Throat? A Systematic Review of Community Pharmacy Sore Throat Services and Their Consequences for General Practice. [PDF]

J Eval Clin Pract
Fischer M, Squalli L, Zabar C, François M.   +3 more
europepmc   +1 more source

Nonadherence and uncontrolled arterial hypertension in Croatia—Insights from the May Measurement Month 2023 campaign and Hunting the silent killer programme

British Journal of Clinical Pharmacology, EarlyView.
Aims To determine the prevalence of non‐adherence to antihypertensive medicines and to identify demographic and behavioral factors associated with non‐adherence in subjects enrolled in the May Measurement Month (MMM) 2023, as part of the permanent public health action Hunting the silent killer.
Valerija Bralić Lang, Ana Soldo, Olgica Velkovski Škopić, Sunčana Vlah Tomičević, Tin Šaban, Andrej Belančić, Ana Jelaković, Josipa Josipović, Mihaela Marinović Glavić, Ivan Pećin, Luka Prgomet, Tajana Željković Vrkić, Bojan Jelaković   +12 more
wiley   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Corrigendum to "A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney function". [PDF]

EClinicalMedicine
Sandhu G, Gordon EA, Adattini J, O'Neill N, Chambers P, Johnson DW, Kelly A, Liauw W, Mallett AJ, Michael M, Mirkov S, Scuderi C, Shingleton J, Siderov J, Sprangers B, Stein BN, Tunnicliffe DJ, Ward RL, ADDIKD Working Group.   +18 more
europepmc   +1 more source

A Narrative Review of Medicare Part D Medication Therapy Management Program Design Challenges and the Development of an Evidence-Informed MTM Benefit Program for a Large Self-Insured Employer. [PDF]

Pharmacy (Basel)
Al Damen L, Zillich AJ, Hudmon KS, Curran GM, Snyder ME.   +4 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source

Implementation and Resource Optimization of an Oral Anticancer Medication Clinical Pharmacy Trainee Program: Operational and Financial Impact at a Tertiary Cancer Centre. [PDF]

Curr Oncol
Peragine C, Charbonneau F, Singh S, DeAngelis C.   +3 more
europepmc   +1 more source

Safety concerns reported by coroners following fentanyl patch fatalities in England, Wales and Northern Ireland between 1997 and 2024

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim To identify safety concerns reported by coroners following fentanyl patch‐related deaths in England, Wales and Northern Ireland, and determine differences in coronial reporting. Methods A systematic case series linking the National Programme on Substance Use Mortality (NPSUM) and the Preventable Deaths Tracker (PDT) (https ...
Eman Mshari, Caroline S. Copeland, Georgia C. Richards   +2 more
wiley   +1 more source